Clinical Development Containment Filler Protein 
The Pharma Data
NOVEMBER 4, 2020
Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). For additional information, please visit [link].
The Pharma Data
DECEMBER 27, 2020
Current intraarticular anti-inflammatory treatments for OA have potentially toxic side effects and may lead to the destruction of cartilage filler proteins. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. About TLC599. Source link.
Expert insights. Personalized for you.
40 
Let's personalize your content